Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the …
FE Lecouvet, DE Oprea-Lager, Y Liu, P Ost… - The Lancet …, 2018 - thelancet.com
Oligometastatic disease represents a clinical and anatomical manifestation between
localised and polymetastatic disease. In prostate cancer, as with other cancers, recognition …
localised and polymetastatic disease. In prostate cancer, as with other cancers, recognition …
[HTML][HTML] Bone metastases are measurable: the role of whole-body MRI and positron emission tomography
DE Oprea-Lager, MCF Cysouw, R Boellaard… - Frontiers in …, 2021 - frontiersin.org
Metastatic tumor deposits in bone marrow elicit differential bone responses that vary with the
type of malignancy. This results in either sclerotic, lytic, or mixed bone lesions, which can …
type of malignancy. This results in either sclerotic, lytic, or mixed bone lesions, which can …
[HTML][HTML] Supervised machine learning enables non-invasive lesion characterization in primary prostate cancer with [68Ga]Ga-PSMA-11 PET/MRI
L Papp, CP Spielvogel, B Grubmüller… - European journal of …, 2021 - Springer
Purpose Risk classification of primary prostate cancer in clinical routine is mainly based on
prostate-specific antigen (PSA) levels, Gleason scores from biopsy samples, and tumor …
prostate-specific antigen (PSA) levels, Gleason scores from biopsy samples, and tumor …
Simplified methods for quantification of 18F-DCFPyL uptake in patients with prostate cancer
BHE Jansen, M Yaqub, J Voortman… - Journal of nuclear …, 2019 - Soc Nuclear Med
Radiolabeled prostate-specific membrane antigen (PSMA) PET has demonstrated
promising results for prostate cancer (PCa) imaging. Quantification of PSMA radiotracer …
promising results for prostate cancer (PCa) imaging. Quantification of PSMA radiotracer …
[HTML][HTML] Kinetic modeling of 68Ga-PSMA-11 and validation of simplified methods for quantification in primary prostate cancer patients
A Ringheim, GC Campos Neto, U Anazodo, L Cui… - EJNMMI research, 2020 - Springer
Background The positron emission tomography (PET) ligand 68 Ga-Glu-urea-Lys (Ahx)-
HBED-CC (68 Ga-PSMA-11) targets the prostate-specific membrane antigen (PSMA) …
HBED-CC (68 Ga-PSMA-11) targets the prostate-specific membrane antigen (PSMA) …
[HTML][HTML] The novel choline kinase inhibitor ICL-CCIC-0019 reprograms cellular metabolism and inhibits cancer cell growth
The glycerophospholipid phosphatidylcholine is the most abundant phospholipid species of
eukaryotic membranes and essential for structural integrity and signaling function of cell …
eukaryotic membranes and essential for structural integrity and signaling function of cell …
[HTML][HTML] Partial-volume correction in dynamic PET-CT: effect on tumor kinetic parameter estimation and validation of simplified metrics
Background Partial-volume effects generally result in an underestimation of tumor tracer
uptake on PET-CT for small lesions, necessitating partial-volume correction (PVC) for …
uptake on PET-CT for small lesions, necessitating partial-volume correction (PVC) for …
[18F]Fluorocholine PET/CT Imaging of Liver Cancer: Radiopathologic Correlation with Tissue Phospholipid Profiling
SA Kwee, MM Sato, Y Kuang, A Franke… - Molecular imaging and …, 2017 - Springer
Abstract Purpose [18 F] fluorocholine PET/CT can detect hepatocellular carcinoma (HCC)
based on imaging the initial steps of phosphatidylcholine synthesis. To relate the diagnostic …
based on imaging the initial steps of phosphatidylcholine synthesis. To relate the diagnostic …
[HTML][HTML] Quantitative 18F-fluorocholine positron emission tomography for prostate cancer: correlation between kinetic parameters and Gleason scoring
JD Schaefferkoetter, Z Wang, MC Stephenson, S Roy… - EJNMMI research, 2017 - Springer
Background The use of radiolabeled choline as a positron emission tomography (PET)
agent for imaging primary tumors in the prostate has been evaluated extensively over the …
agent for imaging primary tumors in the prostate has been evaluated extensively over the …
Repeatability of quantitative 18F-fluoromethylcholine PET/CT studies in prostate cancer
DE Oprea-Lager, G Kramer… - Journal of Nuclear …, 2016 - Soc Nuclear Med
Repeatable quantification is essential when using 18F-fluoromethylcholine PET/CT to
monitor treatment response in prostate cancer. It has been shown that SUV normalized to …
monitor treatment response in prostate cancer. It has been shown that SUV normalized to …